Zenas BioPharmaZBIO stock score: 31/100

$25.04 · -5.22% · Scored Nov 19, 2026

Technical
32
Fundamental
31
News
—

The reading

Zenas BioPharma (ZBIO) scores 31 out of 100, which reads bearish, higher than 5% of Healthcare stocks and 7% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 31, technicals 32.

Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Profitability (Quarterly) at 0 weighs the most against it.

On the daily chart, trend-following indicators average 24 and contrarian oscillators 61 — a split worth reading before trusting the technical total.

Since Aug 23, 2026 the composite has ranged from 31 to 52, and it is down 21 points over the period.

About Zenas BioPharma

Zenas BioPharma (ZBIO) is a biotechnology company that develops treatments for autoimmune diseases. Its lead candidate, obexelimab, is an antibody that binds two proteins on B cells, CD19 and FcγRIIb, to calm the activity of these immune cells without destroying them. In a Phase three trial in IgG4-related disease, a chronic fibro-inflammatory condition that damages organs, obexelimab reduced the risk of disease flares, and Zenas has submitted it for approval in the United States and Europe. Obexelimab is also being studied in systemic lupus erythematosus and relapsing multiple sclerosis. Zenas is developing orelabrutinib, an oral BTK inhibitor licensed from InnoCare Pharma, in Phase three trials for progressive forms of multiple sclerosis. Bristol Myers Squibb holds rights to obexelimab in Japan. Zenas has no approved products and funds its work with cash raised from investors and partnership payments.

In IgG4-related disease, Zenas faces competition from Amgen’s Uplizna and from steroids and other immune therapies, while in multiple sclerosis it competes with Roche, Sanofi and Novartis. Its edge rests on obexelimab’s approach of inhibiting B cells rather than depleting them, convenient self-injection and a pipeline that targets several large autoimmune diseases. Investors who follow ZBIO stock tend to watch the outcome of regulatory reviews for obexelimab and preparations for a commercial launch. Results from lupus and multiple sclerosis trials are closely followed. Cash runway, partnerships and spending on Phase three trials are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward ZBIO’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

31

Pulling it up

  • Quick ratio measures a company's ability to meet short-term obligations with liquid assets.

  • Price target score compares the current stock price to analyst consensus targets.

  • Current assets divided by current liabilities: the ability to pay short-term bills.

Holding it back

  • Earnings Profitability (Quarterly) measures recent profitability using trailing 12-month quarterly data.

  • How reliably yearly earnings grow: the share of years with higher earnings, the compound growth rate, how steady that growth is, and the last two yearly changes.

  • Absolute profitability: whether the company is profitable, its net margin against the sector range, and how consistently it has been profitable over three years.

36 weighted scorers; 3 had no data today and are left out rather than counted as zero.

Technical · daily

28

Pulling it up

  • Bollinger Bands (20-period) plot standard deviations above and below a moving average.

  • Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.

  • Williams %R (7-period) places the close within the last 7 periods' high-low range.

Holding it back

  • Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.

  • Volume Weighted Average Price (VWAP) shows the average price weighted by volume.

  • Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.

62 weighted scorers; 3 had no data today and are left out rather than counted as zero.

Technical score by timeframe

ChartScoreWeight
Hourly281
Daily283
Weekly402

Composite score, last 90 days

05010031Aug 23, 2026Nov 19, 2026Aug 23, 2026: 52Aug 24, 2026: 50Aug 25, 2026: 51Aug 26, 2026: 51Aug 27, 2026: 51Aug 28, 2026: 49Aug 29, 2026: 49Aug 30, 2026: 49Aug 31, 2026: 50Sep 1, 2026: 50Sep 2, 2026: 51Sep 3, 2026: 51Sep 4, 2026: 50Sep 5, 2026: 51Sep 6, 2026: 51Sep 7, 2026: 50Sep 8, 2026: 51Sep 9, 2026: 49Sep 10, 2026: 47Sep 11, 2026: 48Sep 12, 2026: 48Sep 13, 2026: 48Sep 14, 2026: 49Sep 15, 2026: 49Sep 16, 2026: 50Sep 17, 2026: 49Sep 18, 2026: 48Sep 19, 2026: 48Sep 20, 2026: 48Sep 21, 2026: 50Sep 22, 2026: 51Sep 23, 2026: 49Sep 24, 2026: 46Sep 25, 2026: 44Sep 26, 2026: 44Sep 27, 2026: 44Sep 28, 2026: 45Sep 29, 2026: 44Sep 30, 2026: 44Oct 1, 2026: 46Oct 2, 2026: 46Oct 3, 2026: 48Oct 4, 2026: 46Oct 5, 2026: 46Oct 6, 2026: 44Oct 7, 2026: 45Oct 8, 2026: 42Oct 9, 2026: 43Oct 10, 2026: 43Oct 11, 2026: 43Oct 12, 2026: 42Oct 13, 2026: 40Oct 14, 2026: 40Oct 15, 2026: 41Oct 16, 2026: 41Oct 17, 2026: 40Oct 18, 2026: 40Oct 19, 2026: 43Oct 20, 2026: 46Oct 21, 2026: 47Oct 22, 2026: 46Oct 23, 2026: 44Oct 24, 2026: 43Oct 25, 2026: 43Oct 26, 2026: 44Oct 27, 2026: 44Oct 28, 2026: 46Oct 29, 2026: 47Oct 30, 2026: 45Nov 1, 2026: 45Nov 2, 2026: 45Nov 3, 2026: 46Nov 4, 2026: 47Nov 5, 2026: 40Nov 6, 2026: 43Nov 7, 2026: 43Nov 8, 2026: 43Nov 10, 2026: 46Nov 11, 2026: 46Nov 12, 2026: 32Nov 13, 2026: 34Nov 14, 2026: 34Nov 15, 2026: 34Nov 16, 2026: 34Nov 17, 2026: 35Nov 18, 2026: 33Nov 19, 2026: 31
Show the daily numbers
DateComposite
Nov 19, 202631
Nov 18, 202633
Nov 17, 202635
Nov 16, 202634
Nov 15, 202634
Nov 14, 202634
Nov 13, 202634
Nov 12, 202632
Nov 11, 202646
Nov 10, 202646
Nov 8, 202643
Nov 7, 202643
Nov 6, 202643
Nov 5, 202640
Nov 4, 202647
Nov 3, 202646
Nov 2, 202645
Nov 1, 202645
Oct 30, 202645
Oct 29, 202647
Oct 28, 202646
Oct 27, 202644
Oct 26, 202644
Oct 25, 202643
Oct 24, 202643
Oct 23, 202644
Oct 22, 202646
Oct 21, 202647
Oct 20, 202646
Oct 19, 202643
Oct 18, 202640
Oct 17, 202640
Oct 16, 202641
Oct 15, 202641
Oct 14, 202640
Oct 13, 202640
Oct 12, 202642
Oct 11, 202643
Oct 10, 202643
Oct 9, 202643
Oct 8, 202642
Oct 7, 202645
Oct 6, 202644
Oct 5, 202646
Oct 4, 202646
Oct 3, 202648
Oct 2, 202646
Oct 1, 202646
Sep 30, 202644
Sep 29, 202644
Sep 28, 202645
Sep 27, 202644
Sep 26, 202644
Sep 25, 202644
Sep 24, 202646
Sep 23, 202649
Sep 22, 202651
Sep 21, 202650
Sep 20, 202648
Sep 19, 202648
Sep 18, 202648
Sep 17, 202649
Sep 16, 202650
Sep 15, 202649
Sep 14, 202649
Sep 13, 202648
Sep 12, 202648
Sep 11, 202648
Sep 10, 202647
Sep 9, 202649
Sep 8, 202651
Sep 7, 202650
Sep 6, 202651
Sep 5, 202651
Sep 4, 202650
Sep 3, 202651
Sep 2, 202651
Sep 1, 202650
Aug 31, 202650
Aug 30, 202649
Aug 29, 202649
Aug 28, 202649
Aug 27, 202651
Aug 26, 202651
Aug 25, 202651
Aug 24, 202650
Aug 23, 202652

Key facts

Market cap
$1.7B
Sector
Healthcare
Industry
Biotechnology
Beta
-0.86
Risk grade (1–10)
7
Next earnings
Nov 5, 2026

Questions

What is ZBIO's stock rating today?

ZBIO scores 31/100 (Bearish) as of Nov 19, 2026: technical 32, fundamental 31. Scores are recomputed every night.

What does Zenas BioPharma do?

Zenas BioPharma (ZBIO) is a biotechnology company that develops treatments for autoimmune diseases. Its lead candidate, obexelimab, is an antibody that binds two proteins on B cells, CD19 and FcγRIIb, to calm the activity of these immune cells without destroying them.

Is ZBIO stock a buy?

The score is not a buy or sell recommendation. A 31 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the ZBIO score calculated?

98 weighted scorers feed it today: 36 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

ZBIO stock score

HTML

<a href="https://stocksscores.com/stocks/zbio/"><img src="https://stocksscores.com/stocks/zbio/badge.svg" alt="ZBIO stock score" height="20"></a>

Markdown

[![ZBIO stock score](https://stocksscores.com/stocks/zbio/badge.svg)](https://stocksscores.com/stocks/zbio/)